Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.63 |
| ▸ | SHBG | P04278 | 6/20 | 0.63 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.63 |
| ▸ | PGR | P06401 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.63 |
| ▸ | TSHR | P16473 | 5/20 | 0.63 |
| ▸ | AR | P10275 | 4/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | BLM | P54132 | 3/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.63 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.63 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.63 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12153460 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2HSD17B10SHBGNR3C1PGR | |
| SCHEMBL12153584 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2HSD17B10SHBGNR3C1PGR | |
| SCHEMBL13327141 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2HSD17B10SHBGNR3C1PGR | |
| SCHEMBL13327143 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2HSD17B10SHBGNR3C1PGR | |
| SCHEMBL12858782 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2HSD17B10SHBGNR3C1PGR | |
| SCHEMBL12153534 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2HSD17B10SHBGNR3C1PGR | |
| SCHEMBL13304385 | 0.87 | SMN1; SMN2 (0.64) | SMN1; SMN2HSD17B10SHBGNR3C1PGR | |
| SCHEMBL13752656 | 0.85 | CYP19A1 (0.73) | SMN1; SMN2HSD17B10SHBGNR3C1PGR | |
| SCHEMBL4114158 | 0.85 | CYP19A1 (0.73) | SMN1; SMN2HSD17B10SHBGNR3C1PGR | |
| SCHEMBL2508757 | 0.85 | CYP19A1 (0.73) | SMN1; SMN2HSD17B10SHBGNR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210775-A1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20170210775-A1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-9637515-B2 | Guggulphospholipid methods and compositions | JINA PHARMACEUTICALS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637515-B2 | Guggulphospholipid methods and compositions | JINA PHARMACEUTICALS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-2088865-B1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20100151002-A1 | Guggulphospholipid Methods and Compositions | JINA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100151002-A1 | Guggulphospholipid Methods and Compositions | JINA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100151002-A1 | Guggulphospholipid Methods and Compositions | SGMS2, SGMS1, PLA2G5 | SMN1; SMN2 3094/4885HSD17B10 550/4885SHBG 227/4885 |
| US-20170210775-A1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | SGMS1, SGMS2, GGPS1 | SMN1; SMN2 3304/4885HSD17B10 769/4885SHBG 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.